Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13305679 | 0.86 | GSK3B (0.74) | GSK3BCDK2CCNE1 | |
| SCHEMBL13305242 | 0.84 | GSK3B (0.56) | GSK3BCDK2CCNE1 | |
| SCHEMBL12953066 | 0.84 | GSK3B (1.00) | GSK3BCDK2CCNE1 | |
| SCHEMBL13304679 | 0.84 | GSK3B (0.76) | GSK3BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL13305387 | 0.80 | GSK3B (0.61) | GSK3BCDK2CCNE1 | |
| SCHEMBL13305560 | 0.80 | GSK3B (0.65) | GSK3BCDK2CCNE1 | |
| SCHEMBL12954115 | 0.79 | GSK3B (0.52) | GSK3BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL12954031 | 0.79 | GSK3B (0.67) | GSK3BMEN1KMT2AKDM4EHSD17B10 | |
| SCHEMBL13305383 | 0.78 | GSK3B (0.56) | GSK3BCDK2CCNE1 | |
| SCHEMBL13305593 | 0.77 | GSK3B (0.55) | GSK3BCDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |